

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2023

**KINTARA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**001-37823**  
(Commission  
File Number)

**99-0360497**  
(IRS Employer  
Identification No.)

**9920 Pacific Heights Blvd, Suite 150 San Diego, CA**  
(Address of principal executive office)

**92121**  
(Zip Code)

Registrant's telephone number, including area code: (858) 350-4364

N/A  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	KTRA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Termination of Chief Scientific Officer*

As a result of cost-cutting measures adopted by Kintara Therapeutics, Inc. (the “Company”), on November 20, 2023, Dennis Brown was terminated from his position as the Company’s Chief Scientific Officer, effective immediately.

Dr. Brown will continue as a consultant to the Company, in which Dr. Brown will provide advisory services to the Company on a part-time, month-to-month basis for a fee of no more than \$350 per hour.

*Director Fee Deferral*

On November 20, 2023, the Board of Directors of the Company (the “Board”) agreed to defer payment of fees earned by directors for serving on the Board indefinitely, effective immediately, as part of the Company’s focus on lowering costs.

*Chief Executive Officer Retention Payment*

On November 20, 2023, the Compensation Committee of the Board and the Board agreed to pay Robert Hoffman an additional retention payment of \$30,000 per month for his service as the Company’s Chief Executive Officer, effective as of November 1, 2023.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**KINTARA THERAPEUTICS, INC.**

Date: November 21, 2023

By: /s/ Robert E. Hoffman  
Name: Robert E. Hoffman  
Title: Chief Executive Officer

---

